A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib
ConclusionThe successful modeling exercise of erdafitinib preclinical data showed how translational PK-PD modeling might be a tool to help to inform the choice of the doses in FIH studies. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 17, 2021 Category: Cancer & Oncology Source Type: research

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
ConclusionsThe JAK1/2 and TBK1 inhibitor momelotinib in combination with erlotinib did not appear to enhance benefit over the historical data of erlotinib monotherapy in patients withEGFR-mutated NSCLC.ClinicalTrials.gov identifierNCT02206763. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 13, 2021 Category: Cancer & Oncology Source Type: research

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose –escalation phase 1 trial
ConclusionsDostarlimab demonstrated consistent and predictable PK and associated PDy. The observed safety profile was acceptable and characteristic of the anti-PD-1 drug class.Trial registration: ClinicalTrials.gov, NCT02715284. Registration date: March 9, 2016. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 8, 2021 Category: Cancer & Oncology Source Type: research

Integrated exposure –response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer
ConclusionsThe relationships evidenced in this integrated E –R analysis support a favorable benefit-risk profile for lurbinectedin 3.2 mg/m2 q3wk.Trial registrationClinicaltrials.gov: NCT02454972; registered May 27, 2015. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 5, 2021 Category: Cancer & Oncology Source Type: research

The use of vitamin E in preventing taxane-induced peripheral neuropathy
ConclusionOur study did not demonstrate a protective role of vitamin E in decreasing the incidence of CIPN in patients receiving taxane-based chemotherapy. However, the recovery from CIPN was much better as compared to the control arm, which may indicate a role for vitamin E in decreasing the duration and severity of CIPN. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 23, 2021 Category: Cancer & Oncology Source Type: research

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib
ConclusionIpatasertib exhibited rapid absorption and was dose-proportional over a broad dose range. Ipatasertib appeared to be a moderate CYP3A inhibitor when administered at 600  mg and could be administered with or without food in clinical studies.Trail registrationNCT01090960 (registered March 23, 2010); NCT02536391 (registered August 31, 2015). (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 23, 2021 Category: Cancer & Oncology Source Type: research

A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies
ConclusionV and AC can be safely combined. Activity was observed in patients with metastatic breast cancer. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 20, 2021 Category: Cancer & Oncology Source Type: research

Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury
ConclusionHalf-dose glucarpidase seems to be effective in lowering MTX levels to concentrations manageable with continued intensified folinic acid rescue. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 20, 2021 Category: Cancer & Oncology Source Type: research

Retraction Note to: Linc ‑ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR‑124/PTBP1/PKM2 axis
(Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 18, 2021 Category: Cancer & Oncology Source Type: research

Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6 –Cyclin D–Rb pathway
ConclusionsOur pre-clinical evidence provides a rationale of initializing clinical trial of investigating the efficacy of abemaciclib in combination with doxorubicin in osteosarcoma patients. Our work also highlights the therapeutic value of CDK4/6 inhibition in osteosarcoma with proper function of Rb. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 16, 2021 Category: Cancer & Oncology Source Type: research

Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case –control study
ConclusionThe administration of immune checkpoint inhibitors in non-small-cell lung cancer patients with a history of idiopathic interstitial pneumonia might be a viable treatment option and have clinical benefits. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 14, 2021 Category: Cancer & Oncology Source Type: research

Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis
ConclusionLenvatinib treatment should be avoided in patients with Vp4 with a high degree of portal trunk occlusion because of concerns about decreased portal blood flow. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 10, 2021 Category: Cancer & Oncology Source Type: research

Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer
ConclusionPF-06881894 as a single 3- or 6-mg dose prior to definitive surgery, or multiple 6-mg/cycle doses postoperatively, with/without myelosuppressive chemotherapy, was consistent with the clinical pharmacology and safety profile of reference pegfilgrastim.Trial registrationOctober 2017. ClinicalTrials.gov Identifier: NCT02650193. EudraCT Number: 2015-002057-35. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 7, 2021 Category: Cancer & Oncology Source Type: research

EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer
ConclusionExosomal delivery of miR-1915-3p can improve the chemotherapeutic efficacy of oxaliplatin in CRC cells by suppressing the EMT-promoting oncogenes PFKFB3 and USP2. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 2, 2021 Category: Cancer & Oncology Source Type: research

Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck
ConclusionCetuximab-induced rash is associated with better ORR and longer PFS and OS in patients with recurrent/metastatic HNSCC treated with Cetuximab and platinum-based chemotherapy. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 1, 2021 Category: Cancer & Oncology Source Type: research